These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 37067981)
1. Kruppel-like factor 5 enhances proliferation, lipid droplet formation and oxaliplatin resistance in colorectal cancer by promoting fatty acid binding protein 6 transcription. Zuo Q; Xu Q; Li Z; Luo D; Peng H; Duan Z Anticancer Drugs; 2023 Nov; 34(10):1171-1182. PubMed ID: 37067981 [TBL] [Abstract][Full Text] [Related]
2. KLF5 inhibition overcomes oxaliplatin resistance in patient-derived colorectal cancer organoids by restoring apoptotic response. Shen X; Zhang Y; Xu Z; Gao H; Feng W; Li W; Miao Y; Xu Z; Zong Y; Zhao J; Lu A Cell Death Dis; 2022 Apr; 13(4):303. PubMed ID: 35379798 [TBL] [Abstract][Full Text] [Related]
3. Ketogenesis attenuated KLF5 disrupts iron homeostasis via LIF to confer oxaliplatin vulnerability in colorectal cancer. Jiang H; Zeng Y; Jiang X; Xu X; Zhao L; Yuan X; Xu J; Zhao M; Wu F; Li G Biochim Biophys Acta Mol Basis Dis; 2024 Aug; 1870(6):167210. PubMed ID: 38704001 [TBL] [Abstract][Full Text] [Related]
4. Prostaglandin F Wang YJ; Xie XL; Liu HQ; Tian H; Jiang XY; Zhang JN; Chen SX; Liu T; Wang SL; Zhou X; Jin XX; Liu SM; Jiang HQ World J Gastroenterol; 2023 Oct; 29(39):5452-5470. PubMed ID: 37900995 [TBL] [Abstract][Full Text] [Related]
5. Suppression MGP inhibits tumor proliferation and reverses oxaliplatin resistance in colorectal cancer. Huang C; Wang M; Wang J; Wu D; Gao Y; Huang K; Yao X Biochem Pharmacol; 2021 Jul; 189():114390. PubMed ID: 33359068 [TBL] [Abstract][Full Text] [Related]
6. Transcription factor B-MYB activates lncRNA CCAT1 and upregulates SOCS3 to promote chemoresistance in colorectal cancer. Liu F; Wang Y; Cao Y; Wu Z; Ma D; Cai J; Sha J; Chen Q Chem Biol Interact; 2023 Apr; 374():110412. PubMed ID: 36812959 [TBL] [Abstract][Full Text] [Related]
7. Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1. Lin X; Xu L; Gu M; Shao H; Yao L; Huang X Phytomedicine; 2024 Oct; 133():155906. PubMed ID: 39089089 [TBL] [Abstract][Full Text] [Related]
8. The Role of Cyanidin-3- Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099 [TBL] [Abstract][Full Text] [Related]
9. β-hydroxybutyrate resensitizes colorectal cancer cells to oxaliplatin by suppressing H3K79 methylation in vitro and in vivo. Deng M; Yan P; Gong H; Li G; Wang J Mol Med; 2024 Jun; 30(1):95. PubMed ID: 38910244 [TBL] [Abstract][Full Text] [Related]
10. IRF-1 mediated long non-coding RNA PVT1-214 promotes oxaliplatin resistance of colorectal cancer via miR-128 inhibition. Tong D; Zou E; Bai L; Ma J; Guo N; Wang H; Jiang L J BUON; 2020; 25(5):2205-2214. PubMed ID: 33277837 [TBL] [Abstract][Full Text] [Related]
11. LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. Gao R; Fang C; Xu J; Tan H; Li P; Ma L Arch Biochem Biophys; 2019 Mar; 663():183-191. PubMed ID: 30639170 [TBL] [Abstract][Full Text] [Related]
12. Circ_0082182 upregulates the NFIB level via sponging miR-326 to promote oxaliplatin resistance and malignant progression of colorectal cancer cells. Wang Z; Liu J; Yang T; Wang Q; Liang R; Tang J Mol Cell Biochem; 2023 May; 478(5):1045-1057. PubMed ID: 36219357 [TBL] [Abstract][Full Text] [Related]
13. High expression of Krüppel-like factor 5 is associated with poor prognosis in patients with colorectal cancer. Takagi Y; Sakai N; Yoshitomi H; Furukawa K; Takayashiki T; Kuboki S; Takano S; Suzuki D; Kagawa S; Mishima T; Nakadai E; Miyauchi H; Matsubara H; Ohtsuka M Cancer Sci; 2020 Jun; 111(6):2078-2092. PubMed ID: 32279400 [TBL] [Abstract][Full Text] [Related]
14. The c-Myc/miR-27b-3p/ATG10 regulatory axis regulates chemoresistance in colorectal cancer. Sun W; Li J; Zhou L; Han J; Liu R; Zhang H; Ning T; Gao Z; Liu B; Chen X; Ba Y Theranostics; 2020; 10(5):1981-1996. PubMed ID: 32104496 [TBL] [Abstract][Full Text] [Related]
15. TRIM25 regulates oxaliplatin resistance in colorectal cancer by promoting EZH2 stability. Zhou S; Peng J; Xiao L; Zhou C; Fang Y; Ou Q; Qin J; Liu M; Pan Z; Hou Z Cell Death Dis; 2021 May; 12(5):463. PubMed ID: 33966039 [TBL] [Abstract][Full Text] [Related]
16. Krüppel-like factor 5 promotes breast cell proliferation partially through upregulating the transcription of fibroblast growth factor binding protein 1. Zheng HQ; Zhou Z; Huang J; Chaudhury L; Dong JT; Chen C Oncogene; 2009 Oct; 28(42):3702-13. PubMed ID: 19668233 [TBL] [Abstract][Full Text] [Related]
17. Oxaliplatin inhibits colorectal cancer progression by inhibiting CXCL11 secreted by cancer-associated fibroblasts and the CXCR3/PI3K/AKT pathway. Lu C; Zhang C Clin Transl Oncol; 2023 Jan; 25(1):160-172. PubMed ID: 36129606 [TBL] [Abstract][Full Text] [Related]
18. Shikonin potentiates therapeutic efficacy of oxaliplatin through reactive oxygen species-mediated intrinsic apoptosis and endoplasmic reticulum stress in oxaliplatin-resistant colorectal cancer cells. Zhang Z; Shen C; Zhou F; Zhang Y Drug Dev Res; 2023 May; 84(3):542-555. PubMed ID: 36779379 [TBL] [Abstract][Full Text] [Related]
19. IFI6 Downregulation Reverses Oxaliplatin Resistance of Colorectal Cancer Cells by Activating the ROS-Induced p38MAPK Signaling Pathway. Huang C; Zhou T; Ma L; Zhao S Biol Pharm Bull; 2023; 46(1):26-34. PubMed ID: 36596524 [TBL] [Abstract][Full Text] [Related]
20. Antitumor Activity of lncRNA NBAT-1 via Inhibition of miR-4504 to Target to WWC3 in Oxaliplatin-Resistant Colorectal Carcinoma. Li C; Li X J Healthc Eng; 2022; 2022():9121554. PubMed ID: 35494512 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]